噻托溴铵奥达特罗能倍乐是靶向药吗

On May 26, 2017, Boehringer Ingelheim announced the results of a new analysis that provides further evidence that respiratory symptoms improved after the addition of AZA in a Phase III clinical development program and in a population of patients whose asthma symptoms remained uncontrolled on daily maintenance therapy. The results of these data analyzes were presented at the American Thoracic Society (ATS) International Conference in Washington, D.C., USA.

The landmark TIOSPIRTM trial verified that tiotropium bromide olodaterol Respimat 2.5 μg (once daily, 2 puffs) and tiotropium bromide olodaterol Respimat 18 μg have similar safety and effectiveness. Both dosage forms of Slivar are in a leading position in the maintenance treatment of COPD.

Although tiotropium bromide, olodaterol, and Respimat are already on the market in China, you still need to consult your medical companion for the specific price.

The highly anticipated results of the 3-year trial were finally published (September 8, 2013) in the New England Journal of Medicine. The TIOSPIR trial was designed to compare the relative safety and efficacy of tiotropium bromide olodaterol Respimat 2.5 μg (once daily, 2 puffs) and the investigational dose of Slava Respimat 1.25 μg (once daily, 2 puffs) with Slava Respimat 18 μg. The specially designed TIOSPIR trial has appropriate sample size and follow-up time to analyze all-cause mortality and time to first acute exacerbation of COPD in a large population of COPD patients, and has broad inclusion criteria to truly reflect the real-world COPD patient population.

In the results discussion section, Professor Antonio Anzueto, professor of respiratory/emergency medicine at the University of Texas Health Science Center and trial investigator, said: "TIOSPIR is a landmark clinical trial that provides a large sample database to verify the safety and effectiveness of tiotropium bromide, whether it is used with Sutra or Respimat. More importantly, this Evidence from large-sample and rigorously designed clinical trials shows that tiotropium bromide is safe for the majority of COPD patients, including those with a history of heart disease. The key message provided by this large-scale TIOSPIR is that physicians can safely choose this effective treatment for the maintenance period of COPD patients of various severity. "Patients must also pay attention to the precautions when using it, and do not change the dosage of the drug without authorization.

Recommended related hot articles: /newsDetail/83863.html